• Register
  • Login

European Journal of Molecular & Clinical Medicine

  1. Home
  2. Liriodenine: The Prospect For Covid-19

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

Journal Metrics

News

Liriodenine: The Prospect For Covid-19

    Author

    • Ade Zuhrotun

    Biological Pharmacy Department, Faculty of Pharmacy Universitas Padjadjaran, , Jl Raya Bandung- Sumedang KM 21,5 Jatinangor 45363 West Java, Indonesia.

,

Document Type : Research Article

  • Article Information
  • Download
  • Export Citation
  • Statistics
  • Share

Abstract

Until December 13, 2020, the total Covid-19 cases worldwide is 70,476,836 cases and counted 1,599,922 deaths globally since the start of the pandemic. The best medicine for Covid-19 has not been found yet, so this review intended to reveal potency of Liriodenine to overcome and help care for those affected. Liriodenine (C17H9NO3) along with Quinine and its derivate Chloroquine and hydroxychloroquine are include in the compound of nitrogen-containing group or alkaloid. The main mechanism of its activity of Liriodenine is DNA Topoisomerase I and II inhibitors that have cytotoxic effect on several human cell lines such as A549, NCI-H226, SPC-A-1, NPC-TW01, ECV2 and 7111, KB, HEp‑ 2, and against gram (+) and (-) bacteria. Review results showed that Topoisomerase Inhibitor posses dual activity that works on both DNA and RNA, so does Liriodenine predict may affect to RNA virus include SARS-CoV-2 strain or 2019-nCoV. The potency of Liriodenine as new agents for Covid-19 diseases is supported by its other activity antifungal, antiplasmodial (such as Plasmodium falciparum), antidiabetic, antioxidant, and anti-inflammatory (Immunomodulatory) activity. Plants-containing Liriodenine in the world is abundant, not limited to Annonaceae, Magnoliaceae, Lauraceae, Menispermaceae, and Rutaceae. So Liriodenine prospective for developing as herbal therapy or single
compound for Covid-19 diseases

Keywords

  • COVID-19
  • Liriodenine
  • DNA Topoisomerase inhibitor
  • herbal therapy
  • XML
  • PDF 437.95 K
  • RIS
  • EndNote
  • Mendeley
  • BibTeX
  • APA
  • MLA
  • HARVARD
  • VANCOUVER
    • Article View: 276
    • PDF Download: 426
European Journal of Molecular & Clinical Medicine
Volume 8, Issue 2
January 2021
Page 1381-1399
Files
  • XML
  • PDF 437.95 K
Share
Export Citation
  • RIS
  • EndNote
  • Mendeley
  • BibTeX
  • APA
  • MLA
  • HARVARD
  • VANCOUVER
Statistics
  • Article View: 276
  • PDF Download: 426

APA

Zuhrotun, A. (2021). Liriodenine: The Prospect For Covid-19. European Journal of Molecular & Clinical Medicine, 8(2), 1381-1399.

MLA

Ade Zuhrotun. "Liriodenine: The Prospect For Covid-19". European Journal of Molecular & Clinical Medicine, 8, 2, 2021, 1381-1399.

HARVARD

Zuhrotun, A. (2021). 'Liriodenine: The Prospect For Covid-19', European Journal of Molecular & Clinical Medicine, 8(2), pp. 1381-1399.

VANCOUVER

Zuhrotun, A. Liriodenine: The Prospect For Covid-19. European Journal of Molecular & Clinical Medicine, 2021; 8(2): 1381-1399.

  • Home
  • About Journal
  • Editorial Board
  • Submit Manuscript
  • Contact Us
  • Glossary
  • Sitemap

News

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

Newsletter Subscription

Subscribe to the journal newsletter and receive the latest news and updates

© Journal Management System. Powered by ejournalplus